A cilostazol hatásmechanizmusa és szerepe a perifériás veroérbetegség kezelésében

Translated title of the contribution: Mechanism of action and role of cilostazol in treatment of peripheral arterial disease

Katalin Koltai, Katalin Biró, Dávid Kovács, Beáta Csiszár, Kálmán Tóth, Gábor Késmárky

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Intermittent claudication is a typical symptom of lower extremity arterial disease. Cilostazol is a reversible, selective phosphodiesterase-3 inhibitor which has antiplatelet, antithrombotic and vasodilator effects. It is indicated to improve maximal and pain-free walking distance in patients with intermittent claudication in the absence of rest pain or peripheral tissue necrosis. It can be beneficial in diabetic patiens with intermittent claudication, as it has been proved to prevent the development of foot ulcers. In combination with acetyl-salicylic acid it may help maintain stent patency after endovascular intervention and stent implantation. Cilostazol is contraindicated in heart failure. With cilostazol, a clinically proven effective drug has become available in the treatment of intermittent claudication which could improve walking and life quality of patients.

Translated title of the contributionMechanism of action and role of cilostazol in treatment of peripheral arterial disease
Original languageHungarian
Pages (from-to)177-181
Number of pages5
JournalLege Artis Medicinae
Volume25
Issue number4-5
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Mechanism of action and role of cilostazol in treatment of peripheral arterial disease'. Together they form a unique fingerprint.

  • Cite this

    Koltai, K., Biró, K., Kovács, D., Csiszár, B., Tóth, K., & Késmárky, G. (2015). A cilostazol hatásmechanizmusa és szerepe a perifériás veroérbetegség kezelésében. Lege Artis Medicinae, 25(4-5), 177-181.